June 25, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
FDA approves Tryngolza to reduce triglycerides, pancreatitis risk in hypertriglyceridemia
The FDA has approved olezarsen as the first and only therapy, alongside diet, to lower triglycerides and acute pancreatitis risk in patients with severe hypertriglyceridemia, according to a manufacturer press release.Olezarsen (Tryngolza, Ionis Pharmaceuticals), an apolipoprotein C-III inhibitor, is administered once monthly by autoinjector and is available in 50 mg and 80 mg doses. As Healio
625 words~3 min read
